Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 9—September 2021
Research Letter

Genomic Evolution of SARS-CoV-2 Virus in Immunocompromised Patient, Ireland

Maureen Lynch1Comments to Author , Guerrino Macori1, Séamus Fanning, Edel O’Regan, Eoin Hunt, Dermot O’Callaghan, Brian McCullagh, Cormac Jennings, and Anne Fortune
Author affiliations: Mater Misericordiae University Hospital, Dublin, Ireland (M. Lynch, E. O’Regan, E. Hunt, D. O’Callaghan, B. McCullagh, C. Jennings, A. Fortune); University College Dublin-Centre for Food Safety School of Public Health, Physiotherapy & Sports Science, Dublin (G. Macori, S. Fanning)

Cite This Article

Abstract

We examined virus genomic evolution in an immunocompromised patient with prolonged severe acute respiratory syndrome coronavirus 2 infection. Genomic sequencing revealed genetic variation during infection: 3 intrahost mutations and possible superinfection with a second strain of the virus. Prolonged infection in immunocompromised patients may lead to emergence of new virus variants.

The coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to substantial illness and death in immunocompromised patients (1). Outcomes for patients with hematologic malignancies can be poor because of immune suppression associated with cancer itself and chemoimmunotherapy regimens used to treat these cancers (2).

Persistent shedding of SARS-CoV-2 RNA has been described since early in the pandemic; quantitative reverse transcription PCR (qRT-PCR) results have remained positive for 63 days (3). Recent studies of immunocompromised patients have detected infectious virus until 143 days after diagnosis (46). Phylogenetic analysis showed that single-nucleotide polymorphisms (SNPs) could be used to elucidate the transmission routes of SARS-CoV-2 in communities (7). Moreover, it has been demonstrated that intrahost single-nucleotide variants are restricted to specific lineages (8); however, no clear evidence supports a link between prolonged infection and intra-evolutionary dynamics (9).

We report a case of a prolonged clinical infection with persistent virus shedding in a patient with functional B-cell deficiency, hypogammaglobulinemia, and COVID-19. We describe the sequence polymorphisms over time among the 9 whole-virus genome sequences obtained by following the ARTIC tiling-amplicon approach (https://artic.network/resources/ncov/ncov-amplicon-v3.pdf) and using the Illumina MiSeq platform as described (7).

In April 2020, a 52-year-old woman in Dublin, Ireland, sought emergency care for a 5-day history of fever, diarrhea, and fatigue. Five months earlier, she had received a diagnosis of stage 4, grade 1 follicular lymphoma and had since completed 3 cycles of chemotherapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and obinutuzumab (B-cell monoclonal antibody); the last therapy cycle had been completed 7 days before the emergency department visit. During the emergency department visit, SARS-CoV-2 was detected on a nasopharyngeal swab sample by qRT-PCR (Roche FLOW Flex, https://diagnostics.roche.com) with a cycle threshold (Ct) value of 25.04. Chest radiographs showed a typical pattern for COVID-19 infection. The patient received hydroxychloroquine and azithromycin for 5 days. At the time of admission, she had hypogammaglobulinemia and received intravenous immunoglobulin every 4 weeks as supportive therapy.

During her 100-day hospital stay, the patient’s clinical course of illness was protracted, with fevers and oxygen requirements, requiring a 17-day stay in a critical care unit (Appendix). In the hospital, the patient was in a single room with transmission-based air-handling precautions.

During her entire hospital stay, SARS-CoV-2 was detected at varying Ct values in nasopharyngeal swab samples, except for days 31 and 85 when SARS-CoV-2 was not detected. Bronchoalveolar lavage (BAL) performed on day 95 to exclude other pathogens detected SARS-CoV-2 (Ct 30). Serologic testing did not detect antibodies to SARS-CoV-2 (Roche anti-SARS-CoV-2) on days 30, 84, and 103.

Figure

Sequence polymorphisms detected over time among the 9 whole-virus genome sequences from an immunocompromised patient with prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, Ireland. The mutations are represented by different colors; gray lines indicate the polymorphisms common to the 9 whole-virus genome sequences compared with the reference whole-virus genome (GenBank accession no. MN908947, SARS-CoV-2 isolate Wuhan-Hu-1). The infection was confirmed on day 5 of infection (at admission to the emergency department), and the sequencing demonstrated stability of the virus genome sequence on days 19 (T19) and 26 (T26) after the first detection. Green indicates mutations detected in the sample at 47 days after first the emergency department admission (T47), T61, T68, and T76. At sample time T82, the strain exhibited a fourth mutation (pink) corresponding to the second mutation event. On day 95, a bronchoalveolar lavage sample from the patient was positive for SARS-CoV-2 and the whole-virus genome had a different set sequence polymorphism that probably originated from a new infection event. GISAID (https://www.gisaid.org) identification numbers are provided.

Figure. Sequence polymorphisms detected over time among the 9 whole-virus genome sequences from an immunocompromised patient with prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, Ireland. The mutations are represented...

The patient was tested 17 times, and we sequenced all samples that were positive by qRT-PCR with Ct <32.8. All 9 samples that underwent whole-virus genome sequencing (Appendix Figure) belonged to clade 20B, lineage B.1.1. SNP analysis clustered these genomes into 3 groups. Genomes sequenced from the positive samples taken on days 5, 19, and 26 were indistinguishable at the sequence level (Figure). A sample taken on day 47 showed the first mutation event; 3 point mutations were identified in the whole-virus genome sequence data until day 76 after diagnosis. On day 82, genome analysis detected a new SNP (second mutation event). Sequencing of the BAL sample taken on day 95 detected a different set of sequence polymorphisms that most likely originated from a new infection event. SNP analysis indicated 11 point mutations (Appendix Table 1) giving rise to 3 amino acid substitutions in the gene coding for the spike protein (S:S50L, S:A653V, and S:L1186F).

SARS-CoV-2 shedding in this patient with lymphoma, ongoing fevers, and oxygen requirements for 6 months was prolonged. The antibody-mediated ablation of B-cell precursors by B-cell directed monoclonal antibody therapy was most likely responsible for the prolonged virus shedding. This effect, combined with hypogammaglobulinemia, explains the lack of seroconversion and the protracted clinical course.

Sequential sequencing demonstrated intrahost mutations of >2 events (Figure) and accumulation of 4 SNPs. Analysis of a BAL sample taken on day 95 showed 11 point mutations giving rise to 3 aa substitutions in the gene coding for the spike protein. This observation is in accordance with findings of a recent study that detected 7 new mutations in a second virus strain in an immunocompromised patient (10). The BAL findings, along with ongoing symptoms, are suggestive of probable superinfection with cohabitation of 2 virus strains. However, considering that this was the only BAL sampled, we cannot exclude the possibility that the origin of this strain is the result of a different evolutionary path of the original population responsible for the first infection.

The superinfection that we describe was probably a nosocomial infection despite the transmission-based precautions taken in the patient’s single room during her hospital stay. However, no sequence data from other patients or healthcare workers on the ward could be explored to identify the source of infection.

Our report highlights the complex clinical course of SARS-CoV-2 in immunocompromised patients. This genomic analysis identified the ability of the virus to mutate and possibly coexist with another strain, resulting in superinfection in this immunocompromised patient.

Dr. Lynch is a clinical microbiologist in the Mater Misericordiae University Hospital, Dublin, Ireland, with a special interest in molecular diagnostics of respiratory and enteric viruses. Dr. Macori is a research scientist-bioinformatician at University College Dublin, working on the application of novel sequencing technologies for genome diagnosis and epidemiology of major pathogens, including SARS-CoV-2, in Ireland.

Top

Acknowledgment

We thank the patient for allowing this case report to be published.

Top

References

  1. Fung  M, Babik  JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021;72:34050. DOIPubMedGoogle Scholar
  2. Rubinstein  SM, Warner  JL. COVID-19 and haematological malignancy: navigating a narrow strait. Lancet Haematol. 2020;7:e7013. DOIPubMedGoogle Scholar
  3. Li  J, Zhang  L, Liu  B, Song  D. Case report: viral shedding for 60 days in a woman with COVID-19. Am J Trop Med Hyg. 2020;102:12103. DOIPubMedGoogle Scholar
  4. Avanzato  VA, Matson  MJ, Seifert  SN, Pryce  R, Williamson  BN, Anzick  SL, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183:19011912.e9. DOIPubMedGoogle Scholar
  5. Baang  JH, Smith  C, Mirabelli  C, Valesano  AL, Manthei  DM, Bachman  MA, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223:237. DOIPubMedGoogle Scholar
  6. Choi  B, Choudhary  MC, Regan  J, Sparks  JA, Padera  RF, Qiu  X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:22913. DOIPubMedGoogle Scholar
  7. Lucey  M, Macori  G, Mullane  N, Sutton-Fitzpatrick  U, Gonzalez  G, Coughlan  S, et al. Whole-genome sequencing to track severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in nosocomial outbreaks. Clin Infect Dis. 2021;72:e72735. DOIPubMedGoogle Scholar
  8. Armero  A, Berthet  N, Avarre  JC. Intra-host diversity of SARS-Cov-2 should not be neglected: case of the state of Victoria, Australia. Viruses. 2021;13:133. DOIPubMedGoogle Scholar
  9. Wang  Y, Wang  D, Zhang  L, Sun  W, Zhang  Z, Chen  W, et al. Intra-host variation and evolutionary dynamics of SARS-CoV-2 populations in COVID-19 patients. Genome Med. 2021;13:30. DOIPubMedGoogle Scholar
  10. Tarhini  H, Recoing  A, Bridier-Nahmias  AB, Rahi  M, Lambert  C, Martres  P, et al. Long term SARS-CoV-2 infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection. J Infect Dis. 2021;223:15227. DOIPubMedGoogle Scholar

Top

Figure

Top

Cite This Article

DOI: 10.3201/eid2709.211159

Original Publication Date: June 23, 2021

1These authors contributed equally to this article.

Table of Contents – Volume 27, Number 9—September 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Maureen Lynch, Department of Clinical Microbiology, Mater Hospital, Eccles St, Dublin 7, Ireland

Send To

10000 character(s) remaining.

Top

Page created: June 23, 2021
Page updated: August 18, 2021
Page reviewed: August 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external